BioSpace News Archive

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study)

ArisGlobal, the leading provider of life sciences software that automates core drug development functions for over 250 global life sciences companies, today announced it has made a number of new key leadership hires, with the express purpose of preparing for accelerated growth in North America, Europe, and Asia, and new product launches in 2020, according to President and CEO Sankesh Abbhi.

McKesson Corporation (NYSE:MCK) today reported results for the third quarter ended December 31, 2019.

Vital Data Technology, LLC, a leading health IT company serving the payer landscape, today announced the appointment of Chuck Rolfsen as Chief Revenue Officer.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided updated clinical and regulatory guidance on arimoclomol milestones through 2021 in its four indications, amyotrophic lateral sclerosis (ALS)

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib.

Koura’s Zephex® 152a facilitates greater than 90% reduction in inhaler carbon footprints compared to current MDIs [04-February-2020] BOSTON , Feb. 4, 2020 /PRNewswire/ -- Koura (previously known as Mexichem Fluor), a pioneer in the development of next generation propellants, today announced FDA approval to proceed to clinical trials with Zephex® 152a. This new medical

HAYWARD, Calif. , Feb. 4, 2020 /PRNewswire/ -- Potrero Medical announced today that Jeff Mack is joining its executive leadership team as its Chief Financial Officer (CFO) and will report to CEO Joe Urban . Jeff brings more than 30 years of finance and capital markets experience to Potrero Medical.

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced an asset purchase agreement with Wittenstein SE, a privately-held German-based company, to acquire assets associated with the FITBONE® intramedullary lengthening system for limb lengthening of the femur and tibia bones

Feb. 4, 2020 14:00 UTC SAN DIEGO, Calif.--( BUSINESS WIRE )-- Epirium Bio, Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biogenesis and therapeutic approaches to neuromuscular diseases, today announced the appointment of Ransi Somaratne, M.D., as Chief Medical Officer (CMO). In this role, Dr. Somaratne will provide leadership to Epirium’s clinical program to further develop the company’s innovative scientific platform. Dr. Somaratne brings more tha